Last updated: October 26, 2026
Lumason is Bracco’s sulfur hexafluoride lipid-type A microsphere ultrasound contrast agent, marketed as SonoVue outside the United States. Its commercial position rests on two FDA-approved uses: echocardiographic left-ventricular opacification and liver ultrasonography for characterization of focal liver lesions. Bracco does not report Lumason revenue as a standalone line item, so product-level sales, market share, and profitability are not publicly verifiable. The commercial outlook is favorable, but competition from Definity and Optison remains material in cardiac imaging, while manufacturing complexity limits straightforward generic substitution. [1][2]
What is Lumason and how is it used?
Lumason is an injectable ultrasound contrast agent containing sulfur hexafluoride gas within phospholipid microspheres. The microspheres increase ultrasound backscatter and improve visualization of blood pools and lesions.
| Attribute |
Lumason |
| Active component |
Sulfur hexafluoride |
| Dosage form |
Injectable suspension for intravenous use |
| U.S. sponsor |
Bracco Diagnostics Inc. |
| U.S. NDA |
203684 |
| U.S. brand |
Lumason |
| International brand |
SonoVue |
| Initial U.S. approval |
October 2014 |
| Main U.S. uses |
Echocardiography and liver ultrasonography |
| Therapeutic class |
Ultrasound contrast agent |
| Biosimilar pathway |
Not applicable |
| Primary commercial competitors |
Definity, Optison, Sonazoid in selected markets |
The echocardiography indication improves endocardial border delineation when conventional imaging is suboptimal. The liver indication assists characterization of focal liver lesions in adult and pediatric patients. Lumason is not an X-ray or MRI contrast agent and does not compete directly with iodinated contrast media or gadolinium-based agents in every diagnostic setting. [1]
When did Lumason receive FDA approval and exclusivity?
The FDA approved Lumason in 2014 for echocardiography in adults. The agency later expanded its use to liver ultrasonography for focal liver lesion characterization, including pediatric use under the approved labeling. [1][3]
| Milestone |
Date or status |
| FDA approval for echocardiography |
October 2014 |
| FDA liver-imaging expansion |
2016 |
| Current U.S. regulatory status |
FDA-approved prescription product |
| U.S. new chemical entity exclusivity |
Expired |
| Pediatric exclusivity |
Any applicable period would be tied to FDA-granted pediatric studies and is not a current commercial barrier |
| Orphan-drug exclusivity |
Not identified as a principal Lumason exclusivity mechanism |
| Current commercial protection |
Product know-how, manufacturing controls, regulatory approvals, clinical adoption, and any surviving patent claims |
The original regulatory exclusivity period does not protect Lumason today. The active commercial barriers are more likely to be formulation and manufacturing requirements than basic exclusivity tied to the initial FDA approval.
What patents protect Lumason?
Lumason’s core commercial technology is a gas-filled microsphere system with a phospholipid shell. Sulfur hexafluoride itself is an old chemical and does not provide meaningful composition-of-matter protection for the marketed product.
Public patent records associated with sulfur-hexafluoride ultrasound contrast technology include claims directed to microsphere composition, lipid shells, gas entrapment, powder or freeze-dried preparation, reconstitution, and manufacturing processes. Patent families in this technical area have been filed by Bracco-related entities and other contrast-agent developers. Many early foundational patents have reached their ordinary U.S. expiration periods.
A precise current patent count cannot be established from the FDA label alone. The key distinction is between:
- expired foundational patents covering broad gas-filled microspheres;
- later patents covering specific shell compositions or production conditions;
- process patents covering manufacturing and reconstitution;
- foreign patents with different expiration dates and claim scope; and
- regulatory protection based on the approved product dossier rather than patent rights.
The U.S. product label does not provide a complete freedom-to-operate analysis. Patent status must be assessed family by family, including terminal disclaimers, patent-term adjustments, continuations, and foreign counterparts. [1][4]
Is Lumason listed in the Orange Book?
Lumason is an approved NDA product, but an Orange Book listing does not automatically establish a broad or commercially decisive patent barrier. Any current patent information must be checked against the FDA’s live Approved Drug Products with Therapeutic Equivalence Evaluations database and the applicable NDA patent listing record. [5]
Because Lumason is a complex injectable microsphere suspension, the absence of a strong listed patent position would not eliminate development risk for a competing applicant. A competitor would still need to demonstrate equivalence or otherwise support approval through an appropriate regulatory pathway.
When does Lumason lose exclusivity?
Lumason has already lost the exclusivity associated with its original U.S. approval. The more relevant question is when a competitor can obtain approval and reliably reproduce the product.
For a complex injectable contrast agent, market entry can be delayed by:
- inability to match microsphere size distribution;
- instability during storage;
- incomplete gas retention;
- inconsistent reconstitution;
- differences in phospholipid composition;
- container-closure performance;
- dose-delivery variability;
- clinical performance differences in echocardiography or liver imaging; and
- FDA requirements for comparative quality and clinical data.
An applicant could pursue an ANDA if FDA determines that the reference product has an appropriate therapeutic-equivalence framework. A 505(b)(2) application may be more practical if the product differs in formulation, manufacturing process, device presentation, or clinical evidence requirements. The pathway depends on FDA’s product-specific expectations and the proposed product’s degree of similarity.
What generic entry risks exist for Lumason?
Generic entry risk is moderate rather than immediate. The active gas is inexpensive, but the product is not economically reducible to sulfur hexafluoride. The value lies in the reproducible microsphere system and the validated manufacturing process.
Manufacturing and IP barriers
Critical technical variables include:
- microsphere diameter and size distribution;
- shell composition and mechanical response;
- sulfur hexafluoride loading;
- particle concentration;
- reconstitution time;
- suspension uniformity;
- stability after reconstitution;
- extractables and leachables;
- syringe or vial compatibility; and
- sterility assurance.
A competitor may be able to design around expired patents while still facing substantial process-development and validation costs. This gives Bracco an operational advantage even if formal patent protection is limited.
Paragraph IV challenges
No widely reported, commercially consequential Paragraph IV litigation against Lumason has been identified in the public record reviewed for this analysis. That does not establish that no patent certification or challenge has ever been filed. It indicates that Lumason has not generated the level of public generic litigation associated with major small-molecule blockbusters.
The absence of visible Paragraph IV litigation is consistent with a market in which technical and regulatory complexity may be more important than patent expiration.
How does Lumason compare with Definity and Optison?
Definity is the strongest U.S. cardiac-imaging competitor. It is marketed by Lantheus Medical Imaging and uses perflutren lipid microspheres. Optison, marketed by GE HealthCare, uses perflutren protein-type A microspheres.
| Product |
Company |
Primary U.S. positioning |
Main competitive issue |
| Lumason |
Bracco |
Echocardiography and liver imaging |
Broad diagnostic utility, global SonoVue franchise |
| Definity |
Lantheus |
Echocardiography and cardiac imaging |
Strong U.S. physician familiarity and commercial scale |
| Optison |
GE HealthCare |
Echocardiography |
Established hospital presence and alternative microsphere technology |
| Sonazoid |
GE HealthCare |
Liver imaging in selected international markets |
Different imaging profile and geographic availability |
Lumason has an important differentiation point because its U.S. label covers both cardiac imaging and liver lesion characterization. Definity is more concentrated in echocardiography, while Sonazoid has a stronger role in selected liver-imaging markets outside the United States.
The products are not automatically interchangeable. Hospitals may consider imaging performance, supply reliability, reimbursement, pharmacy handling, dosing workflow, and physician preference. Formulary decisions can therefore preserve brand-level demand after formal exclusivity ends.
What is Lumason’s financial trajectory?
Bracco does not publicly disclose Lumason or SonoVue revenue as a separate product line. Bracco Group financial reporting aggregates products within broader imaging businesses, preventing an independently verified Lumason revenue series.
The product’s financial trajectory can be assessed through commercial drivers:
| Driver |
Effect on Lumason |
| Expansion of contrast-enhanced ultrasound |
Increases addressable demand |
| Cardiac ultrasound utilization |
Supports recurring hospital use |
| Liver lesion characterization |
Broadens use beyond cardiology |
| Pediatric imaging |
Increases institutional and specialty use |
| Hospital purchasing pressure |
Limits price expansion |
| Definity competition |
Restricts U.S. cardiac share gains |
| Manufacturing capacity |
Can constrain supply and revenue |
| International SonoVue adoption |
Supports geographic diversification |
Bracco’s broader imaging business includes contrast agents, imaging systems, and related diagnostic products. Public group-level revenue therefore cannot be attributed to Lumason without management disclosure or third-party prescription and shipment data. [6]
The product likely has attractive gross-margin characteristics because it is a differentiated diagnostic injectable sold into hospital and imaging-center workflows. Those margins are offset by sterile manufacturing, specialized filling and packaging, quality control, pharmacovigilance, and distribution costs.
What is the commercial outlook for Lumason?
Lumason’s growth opportunity is tied to expanded use of contrast-enhanced ultrasound rather than a price-led strategy. Three factors support demand.
First, ultrasound is widely available and avoids ionizing radiation. Second, contrast-enhanced ultrasound can improve lesion characterization in settings where conventional ultrasound is inconclusive. Third, the liver indication expands utilization beyond cardiology.
The principal constraints are hospital budgets, limited physician familiarity in some regions, reimbursement variation, and competition from MRI and CT. Contrast-enhanced ultrasound also requires trained operators and appropriate ultrasound equipment. Product adoption therefore depends on workflow integration, not only regulatory approval.
Bracco’s global SonoVue presence gives the product geographic reach beyond the United States. Geographic patent and regulatory positions vary. U.S. approval does not establish approval in Europe, China, Japan, or other markets, and patent expiration dates differ by jurisdiction.
What patent litigation and settlement agreements affect Lumason?
No major publicly reported U.S. patent litigation or generic settlement involving Lumason has been identified as a material current market event. No established authorized-generic arrangement is publicly associated with the product.
The absence of a settlement does not remove future litigation risk. A new entrant could trigger disputes over:
- microsphere shell composition;
- manufacturing conditions;
- reconstitution technology;
- container-closure systems;
- stability specifications;
- use in echocardiography; or
- liver-imaging methods.
Method-of-use claims may have commercial value where they cover a defined imaging protocol, patient population, dose, or diagnostic application. Their practical enforceability depends on claim language and whether the allegedly infringing conduct is attributable to the manufacturer, provider, or patient.
What generic launch scenarios are most likely?
Three scenarios are commercially plausible.
Scenario 1: No near-term U.S. generic
Bracco retains share through manufacturing scale, hospital familiarity, and the difficulty of demonstrating equivalence for a microsphere suspension. Competition remains primarily branded.
Scenario 2: One complex generic or 505(b)(2) entrant
A competitor enters after completing extensive formulation, analytical, and clinical work. Pricing pressure is moderate because hospitals value supply continuity and clinical consistency.
Scenario 3: Multiple entrants
Several manufacturers establish products with comparable performance. Contracting pressure increases, Lumason’s cardiac share declines, and Bracco relies more heavily on liver imaging, international markets, and bundled hospital relationships.
The third scenario would require substantial investment and favorable FDA guidance. It is less likely than branded competition continuing to dominate the near-term U.S. market.
How strong is the Lumason patent estate?
The patent estate appears stronger as a technical and manufacturing portfolio than as a remaining basic composition-of-matter barrier. Foundational microsphere concepts are old, while later claims may protect narrower formulations, processes, or uses.
| Patent-strength dimension |
Assessment |
| Active ingredient protection |
Weak; sulfur hexafluoride is old |
| Foundational microsphere protection |
Largely mature or expired |
| Formulation protection |
Potentially meaningful but claim-specific |
| Manufacturing protection |
Potentially meaningful |
| Method-of-use protection |
Relevant for cardiac and liver applications |
| Regulatory exclusivity |
Expired for the original approval |
| Trade-secret value |
High for process control and scale-up |
| Generic substitution risk |
Moderate |
The strongest practical protection is likely the combination of process know-how, validated specifications, regulatory history, supply reliability, and clinical familiarity.
Key Takeaways
- Lumason is Bracco’s U.S. sulfur hexafluoride ultrasound contrast agent under NDA 203684.
- FDA-approved uses cover echocardiography and liver ultrasonography for focal liver lesion characterization.
- Original U.S. regulatory exclusivity has expired.
- No major current Paragraph IV litigation or generic settlement has been publicly identified.
- Patent protection is likely more important for specific formulations and manufacturing processes than for sulfur hexafluoride itself.
- Definity is the principal U.S. cardiac competitor; Optison remains an alternative.
- Bracco does not disclose standalone Lumason or SonoVue revenue.
- Revenue growth depends on contrast-enhanced ultrasound adoption, liver imaging expansion, and international SonoVue demand.
- Generic entry is technically more difficult than for a conventional small-molecule injectable.
- The commercial risk is moderate, with manufacturing and regulatory barriers partially offsetting the absence of strong basic exclusivity.
FAQs About Lumason Market and Patent Risk
Is Lumason a biologic or a biosimilar product?
No. Lumason is a chemically defined ultrasound contrast agent containing sulfur hexafluoride gas in lipid microspheres. Biosimilar regulation does not apply.
Is Lumason interchangeable with Definity?
No automatic interchangeability exists. The products use different microsphere technologies and are selected based on labeling, imaging performance, hospital policy, supply, and reimbursement.
Does Lumason have a composition-of-matter patent?
Sulfur hexafluoride is an old substance. Any meaningful remaining protection would more likely involve the microsphere formulation, manufacturing process, device presentation, or method of use.
Can a generic company file an ANDA for Lumason?
Potentially, but the regulatory route depends on FDA’s determination of product equivalence and the applicant’s formulation and manufacturing design. A 505(b)(2) pathway may be relevant for a materially different complex injectable.
What is the biggest commercial threat to Lumason?
The largest near-term threat is sustained competition from Definity in U.S. echocardiography, followed by pricing pressure from a technically successful complex generic or 505(b)(2) entrant.
References
- U.S. Food and Drug Administration. (2024). Lumason prescribing information. Bracco Diagnostics Inc. https://www.accessdata.fda.gov
- Bracco Imaging. (2024). SonoVue: Ultrasound contrast agent product information. https://www.braccoimaging.com
- U.S. Food and Drug Administration. (2016). FDA approves Lumason for liver ultrasonography. https://www.fda.gov
- United States Patent and Trademark Office. (2024). Patent Center and Patent Examination Data System. https://patents.uspto.gov
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob
- Bracco Group. (2024). Corporate and financial information. https://www.bracco.com
